Guess which ASX biotech share just rocketed 56% on new Alzheimer's drug trial results

This biotech company is soaring ahead today.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • This ASX biotech share exploded 56% today before pulling back
  • The company announced positive clinical trial data
  • The ASX 200 is in the red today 

The S&P/ASX 200 Index (ASX: XJO) is down 1.69% today, but one ASX biotech share is bucking the trend.

The Actinogen Medical Ltd (ASX: ACW) share price soared 56% in early trade before pulling back. The company's share price is up 30% at the time of writing and is currently trading at 12.5 cents.

Let's take a look at why this biotechnology company is having a good day.

Trial results

Actinogen shares are exploding today on the back of news on an Alzheimers Disease (AD) clinical trial.

The company advised of positive phase 2a clinical data from an AD biomarker study.

Xanamem had a therapeutic impact on patients with a biomarker-positive blood profile.

Xanamem is the company's drug candidate to treat Alzheimer's disease.

Patients who had elevated blood pTau showed a "clinically significant Xanamem effect on the CDR-SB endpoint".

CDR-CB is a well known primary endpoint for trials in patients with early-stage AD, Actinogen said.

Actinogen highlighted that this means using this endpoint in future trials will be "straightforward and uncontroversial".

Commenting on the news, CEO and managing director Dr Steven Gourlay said:

Xanamem has the potential to be a novel daily oral therapy for Alzheimer's Disease and other conditions that could be safely used alone or in combination with other therapies.

The results affirm our confidence in the upcoming clinical trials that will confirm if Xanamem can make a significant improvement in the lives of patients and their families living with serious neurological and psychiatric conditions.

Actinogen share price snapshot

The Actinogen Medical share price has climbed 14% in the past year, while it has fallen 22% year to date.

For perspective, the ASX 200 has fallen nearly 9% in the past year and 10.5% in 2022.

This ASX biotech share has a market capitalisation of more than $224 million based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Is this a new threat for CSL shares?

There's a new wonder drug on the scene. Should shareholders be concerned?

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Earnings Results

What's with the Neuren Pharmaceuticals share price today?

The full market reaction to the Daybue developer's FY23 earnings report won't be seen until tomorrow.

Read more »

private health insurance diagram.
Healthcare Shares

What's going on with the Medibank share price today?

Shareholders will be happy to see Medibank shares drop in value today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Mesoblast share price tumbles on US$32.5m half-year loss

This biotech continues to burn cash.

Read more »

Health professional working on his laptop.
Healthcare Shares

Ramsay Health Care share price falls on profit crunch and dividend cut

This private hospital operator continues to battle with higher costs.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Guess which ASX pharmaceuticals stock is up 400% in 2 days

Big returns have been generated from this pharma stock this week.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 200 pharmaceuticals stock crashing 15% today?

Investors haven't responded positively to a sales update.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Share Gainers

This small-cap ASX stock just rocketed 39%. What's doing?

A stock no one has heard of is lighting up trading screens on Wednesday. You might hear this name more…

Read more »